Pembrolizumab, in addition to chemotherapy, is in clinical development for adults with urothelial cancer that is advanced or metastatic. Urothelial cancer occurs on the lining of the bladder and other parts of the urinary system. In advanced urothelial cancer, the cancer has grown into deeper layers including connective tissue or muscle. In metastatic urothelial cancer, the cancer has spread to other parts of the body, such as the liver or bones. Urothelial cancer usually occurs in patients aged 60 years and older, and many patients have other medical conditions, or are not fit enough to be given certain treatments.
Pembrolizumab is a drug administered by intravenous infusion which stimulates the body’s own immune system to fight cancer cells. If licensed, pembrolizumab in addition to chemotherapy could provide an additional or alternative treatment option to patients who currently have limited treatment options.
Daratumumab injected under the skin (subcutaneous formulation) is in development for the treatment multiple myeloma (MM) as an alternative to currently approved daratumumab intravenous formulation. MM is a rare, incurable cancer of the plasma cells in the bone marrow where large amounts of abnormal plasma cells are produced and interfere with the production of platelets, red and white blood cells. People with MM will experience periods of time without symptoms followed by periods when the illness comes back (‘relapsed’ MM). Eventually the periods without symptoms will shorten and the illness will become immune to the drugs given to treat it (‘refractory’ MM).